The Roche (ROG: SIX) therapy Ocrevus (ocrelizumab) was only approved in 2017, but it has already become the multiple sclerosis (MS) market leader in its class, recording sales of $1.72 billion in the first half of 2019.
By 2025, annual sales of the drug will reach $6.8 billion, according to the data and analytics company GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze